Cargando…

Protocol for randomized controlled trial to evaluate the safety and feasibility of a novel helmet to deliver transcranial light emitting diodes photobiomodulation therapy to patients with Parkinson’s disease

INTRODUCTION: Parkinson’s disease (PD) is the second most common, progressive, and debilitating neurodegenerative disease associated with aging and the most common movement disorder. Photobiomodulation (PBM), the use of non-thermal light for therapeutic purposes using laser or light emitting diodes...

Descripción completa

Detalles Bibliográficos
Autores principales: McGee, Claire, Liebert, Ann, Herkes, Geoffrey, Bicknell, Brian, Pang, Vincent, McLachlan, Craig S., Kiat, Hosen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428720/
https://www.ncbi.nlm.nih.gov/pubmed/36061601
http://dx.doi.org/10.3389/fnins.2022.945796
_version_ 1784779183274065920
author McGee, Claire
Liebert, Ann
Herkes, Geoffrey
Bicknell, Brian
Pang, Vincent
McLachlan, Craig S.
Kiat, Hosen
author_facet McGee, Claire
Liebert, Ann
Herkes, Geoffrey
Bicknell, Brian
Pang, Vincent
McLachlan, Craig S.
Kiat, Hosen
author_sort McGee, Claire
collection PubMed
description INTRODUCTION: Parkinson’s disease (PD) is the second most common, progressive, and debilitating neurodegenerative disease associated with aging and the most common movement disorder. Photobiomodulation (PBM), the use of non-thermal light for therapeutic purposes using laser or light emitting diodes (LED) is an emerging non-invasive treatment for a diverse range of neurological conditions. The main objectives of this clinical trial are to investigate the feasibility, safety, tolerability, and efficacy of a novel transcranial LED helmet device (the “PDNeuro”) in the alleviation of symptoms of PD. METHODS AND ANALYSIS: This is a 24-week, two-arm, triple-blinded randomized placebo-controlled clinical trial of a novel transcranial “PDNeuro” LED Helmet, comparing an active helmet to a sham helmet device. In a survey, 40 PD participants with Hoehn and Yahr Stage I–III during ON periods will be enrolled and randomly assigned into two groups. Both groups will be monitored weekly for the safety and tolerability of the “PDNeuro” LED Helmet. Clinical signs and symptoms assessed will include mobility, fine motor skills and cognition, with data collected at baseline, 12 weeks, and 24 weeks. Assessment tools include the TUG, UPDRS, and MoCA all validated for use in PD patients. Patient’s adherence to the device usage and participant drop out will be monitored weekly. At 12 weeks both placebo and treatment groups will crossover and placebo participants offered the treatment. The main indicator for clinical efficacy of the “PDneuro” Helmet is evidence of sustained improvements in motor and non-motor symptoms obtained from participant self-reported changes, carer reporting of changes and objective reassessment by the investigators. The outcomes will assist in a future larger randomized trial design. CLINICAL TRIAL REGISTRATION: [https://www.anzctr.org.au], identifier [12621001722886].
format Online
Article
Text
id pubmed-9428720
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94287202022-09-01 Protocol for randomized controlled trial to evaluate the safety and feasibility of a novel helmet to deliver transcranial light emitting diodes photobiomodulation therapy to patients with Parkinson’s disease McGee, Claire Liebert, Ann Herkes, Geoffrey Bicknell, Brian Pang, Vincent McLachlan, Craig S. Kiat, Hosen Front Neurosci Neuroscience INTRODUCTION: Parkinson’s disease (PD) is the second most common, progressive, and debilitating neurodegenerative disease associated with aging and the most common movement disorder. Photobiomodulation (PBM), the use of non-thermal light for therapeutic purposes using laser or light emitting diodes (LED) is an emerging non-invasive treatment for a diverse range of neurological conditions. The main objectives of this clinical trial are to investigate the feasibility, safety, tolerability, and efficacy of a novel transcranial LED helmet device (the “PDNeuro”) in the alleviation of symptoms of PD. METHODS AND ANALYSIS: This is a 24-week, two-arm, triple-blinded randomized placebo-controlled clinical trial of a novel transcranial “PDNeuro” LED Helmet, comparing an active helmet to a sham helmet device. In a survey, 40 PD participants with Hoehn and Yahr Stage I–III during ON periods will be enrolled and randomly assigned into two groups. Both groups will be monitored weekly for the safety and tolerability of the “PDNeuro” LED Helmet. Clinical signs and symptoms assessed will include mobility, fine motor skills and cognition, with data collected at baseline, 12 weeks, and 24 weeks. Assessment tools include the TUG, UPDRS, and MoCA all validated for use in PD patients. Patient’s adherence to the device usage and participant drop out will be monitored weekly. At 12 weeks both placebo and treatment groups will crossover and placebo participants offered the treatment. The main indicator for clinical efficacy of the “PDneuro” Helmet is evidence of sustained improvements in motor and non-motor symptoms obtained from participant self-reported changes, carer reporting of changes and objective reassessment by the investigators. The outcomes will assist in a future larger randomized trial design. CLINICAL TRIAL REGISTRATION: [https://www.anzctr.org.au], identifier [12621001722886]. Frontiers Media S.A. 2022-08-17 /pmc/articles/PMC9428720/ /pubmed/36061601 http://dx.doi.org/10.3389/fnins.2022.945796 Text en Copyright © 2022 McGee, Liebert, Herkes, Bicknell, Pang, McLachlan and Kiat. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
McGee, Claire
Liebert, Ann
Herkes, Geoffrey
Bicknell, Brian
Pang, Vincent
McLachlan, Craig S.
Kiat, Hosen
Protocol for randomized controlled trial to evaluate the safety and feasibility of a novel helmet to deliver transcranial light emitting diodes photobiomodulation therapy to patients with Parkinson’s disease
title Protocol for randomized controlled trial to evaluate the safety and feasibility of a novel helmet to deliver transcranial light emitting diodes photobiomodulation therapy to patients with Parkinson’s disease
title_full Protocol for randomized controlled trial to evaluate the safety and feasibility of a novel helmet to deliver transcranial light emitting diodes photobiomodulation therapy to patients with Parkinson’s disease
title_fullStr Protocol for randomized controlled trial to evaluate the safety and feasibility of a novel helmet to deliver transcranial light emitting diodes photobiomodulation therapy to patients with Parkinson’s disease
title_full_unstemmed Protocol for randomized controlled trial to evaluate the safety and feasibility of a novel helmet to deliver transcranial light emitting diodes photobiomodulation therapy to patients with Parkinson’s disease
title_short Protocol for randomized controlled trial to evaluate the safety and feasibility of a novel helmet to deliver transcranial light emitting diodes photobiomodulation therapy to patients with Parkinson’s disease
title_sort protocol for randomized controlled trial to evaluate the safety and feasibility of a novel helmet to deliver transcranial light emitting diodes photobiomodulation therapy to patients with parkinson’s disease
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428720/
https://www.ncbi.nlm.nih.gov/pubmed/36061601
http://dx.doi.org/10.3389/fnins.2022.945796
work_keys_str_mv AT mcgeeclaire protocolforrandomizedcontrolledtrialtoevaluatethesafetyandfeasibilityofanovelhelmettodelivertranscraniallightemittingdiodesphotobiomodulationtherapytopatientswithparkinsonsdisease
AT liebertann protocolforrandomizedcontrolledtrialtoevaluatethesafetyandfeasibilityofanovelhelmettodelivertranscraniallightemittingdiodesphotobiomodulationtherapytopatientswithparkinsonsdisease
AT herkesgeoffrey protocolforrandomizedcontrolledtrialtoevaluatethesafetyandfeasibilityofanovelhelmettodelivertranscraniallightemittingdiodesphotobiomodulationtherapytopatientswithparkinsonsdisease
AT bicknellbrian protocolforrandomizedcontrolledtrialtoevaluatethesafetyandfeasibilityofanovelhelmettodelivertranscraniallightemittingdiodesphotobiomodulationtherapytopatientswithparkinsonsdisease
AT pangvincent protocolforrandomizedcontrolledtrialtoevaluatethesafetyandfeasibilityofanovelhelmettodelivertranscraniallightemittingdiodesphotobiomodulationtherapytopatientswithparkinsonsdisease
AT mclachlancraigs protocolforrandomizedcontrolledtrialtoevaluatethesafetyandfeasibilityofanovelhelmettodelivertranscraniallightemittingdiodesphotobiomodulationtherapytopatientswithparkinsonsdisease
AT kiathosen protocolforrandomizedcontrolledtrialtoevaluatethesafetyandfeasibilityofanovelhelmettodelivertranscraniallightemittingdiodesphotobiomodulationtherapytopatientswithparkinsonsdisease